Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Lymphoma
08:44

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Incorporating Nivolumab and Brentuximab Vedotin Into Radiation-Free Treatment of Early Stage cHL

FEATURING Ann LaCasce
  • 261 views
  • January 6, 2025
  • 2
13:39

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With MCL - MAVO Phase 1/2 Study

FEATURING Austin Kim
  • 37 views
  • December 13, 2024
12:43

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Bispecific Antibodies or CAR T-Cells for Indolent B-NHL?

FEATURING Caron Jacobson
  • 123 views
  • October 18, 2023
05:36

Oncology Data Advisor

Phase 1/2 EPCORE NHL-2 Trial: Investigating Epcoritamab for R/R Follicular Lymphoma & Beyond

FEATURING Reid Merryman
  • 58 views
  • September 11, 2023
10:36

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in High-Risk FL Regardless of POD24 Status"

FEATURING Reid Merryman
  • 292 views
  • June 27, 2023
  • 2
19:42

Indy Hematology Review

Beyond Hyperviscosity: 80 Years and Counting - Treatment of Waldenstrom’s Macroglobulinemia

FEATURING Steven Treon
  • 36 views
  • April 19, 2023
12:50

ASH 2022 Conference Coverage

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

FEATURING Jorge Castillo
  • 64 views
  • December 22, 2022
  • 1
13:46

Dana-Farber Cancer Institute

Venetoclax in Previously Treated Waldenström Macroglobulinemia

FEATURING Jorge Castillo
  • 25 views
  • March 23, 2022